Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Azacitidine in NPM1-mutated AML
NCT03769532Phase 2Terminated
- Sponsor
- Technische Universität Dresden
- Start
- Aug 2019
- Primary completion
- Feb 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in acute myeloid leukemia (AML), sponsored by Technische Universität Dresden. Primary endpoint: Proportion of event-free patients at 24 weeks. Started Aug 2019; status: terminated.
02
Drugs
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03769532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03769532.